엠아이텍 Stock: price and insider trades · South Korea

엠아이텍 is a Health Care company. Its directors and officers file their transactions with DART (FSS). The last twelve months, up to 1 November 2026, brought 4 filings signed by 4 insiders.

The record shows 2 purchases on the open market, made by 2 insiders, against 1 sale by 1 insider. The totals do not cover 3 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 board member.

The last insider purchase was made public on 2 April 2026, 222 days ago. The median gap between a trade and its publication by DART (FSS) is 7 days. This delay matters because a trade only becomes useful information once it is public.

Compared with its exchange (2,655 companies, median 7 filings), a count of 4 filings is below the norm. Looking back to 2021, when coverage begins, insiders filed 4 purchases and 12 sales.

In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.